Multidisciplinary Management of Breast Cancer (BST)
This session has been identified and designated as Credit to Meet ACS Accreditation/Verification Requirements for Breast. Learn more about ACS Accreditation/Verification Requirements.
Breast cancer is a complex disease and we have witnessed profound transformations in breast cancer therapy. A multidisciplinary approach is essential for the management. The aim of this educational program is to discuss the current and future states of multi-modality management of breast cancer by focusing on what general surgeons should know.
Moderator: Atilla Soran, MD, FACS, Gibsonia, PA
Co-Moderator: Faina Nakhlis, MD, FACS, Boston, MA
Role of Neoadjuvant Therapy in Downstaging the Axilla
Beth Overmoyer, MD, FACP, Boston, MA
Imaging Axilla and Response to Neoadjuvant Therapy
Khai Tran, MD, Sacremento, CA
Tailored Axillary Surgery
Ronald R. Johnson, MD, FACS, Sewickley, PA
Tailored Radiation Therapy
Julia R. White, MD, Columbus, OH
Sponsored by the Commission on Cancer and the Advisory Council for General Surgery
- Practicing surgeons
- Apply new knowledge and ideas to improve their surgical practice
- Adapt concepts and quality measures in support of research advancements
- Enhance the quality of patient care
For questions about the course, please contact email@example.com.
In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all relevant financial relationships with any commercial interest. For additional information, please visit the ACCME website.
The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during a activity, please report it on the evaluation.
(Download the full list of disclosures).
Faculty and Disclosures
Atilla Soran MD, FACS - Nothing to Disclose
Beth Overmoyer, MD, FACP - Eisai: Research Support: Principal Investigator Clinical Trial; Genentech: Research Support: Principal Investigator Clinical Trial; GTX: Research Support: Principal Investigator Clinical Trial; Incyte: Research Support: Principal Investigator Clinical Trial
Faina Nakhlis MD, FACS - Nothing to Disclose
Julia R. White MD - Nothing to Disclose
Khai A Tran MD - Nothing to Disclose
Ronald R. Johnson MD, FACS - Nothing to Disclose
Program Committee and Disclosures
CHAIR: Henri R. Ford, MD, MHA, FACS, FAAP, FRCSEng(Hon), Miami, FL - Nothing to Disclosure
VICE-CHAIR: David T. Cooke, MD, FACS, Sacramento, CA - Nothing to Disclosure
David C. Borgstrom, MD, FACS, Morgantown, WV - Nothing to Disclosure
Daniel L. Dent, MD, FACS, San Antonio, TX - Nothing to Disclosure
Roger R. Dmochowski, MD, FACS, Nashville, TN - Allergen: Honoraria: Consultant
Cynthia D. Downard, MD, FACS, Louisville, KY - Nothing to Disclosure
Audra A. Duncan, MD, FACS, London, ON - Nothing to Disclosure
Mariam F. Eskander, MD, Boston, MA - Nothing to Disclosure
Paula Ferrada, MD, FACS, Richmond, VA - Nothing to Disclosure
Neil H. Hyman, MD, FACS, Chicago, IL - Nothing to Disclosure
Martin S. Karpeh, Jr., MD, FACS, New York, NY - Nothing to Disclosure
Dennis H. Kraus, MD, FACS, New York, NY - Nothing to Disclosure
Kenneth W. Sharp, MD, FACS, Nashville, TN - Nothing to Disclosure
Daniel M. Herron, MD, FACS, FASBMS, New York, NY - Nothing to Disclosure
Edith Tzeng, MD, FACS, Pittsburgh, PA - Nothing to Disclosure
Barbara Lee Bass, MD, FACS, FRCSEng(Hon), FRCSI(Hon), FCOSECSA(Hon), Houston, TX - Nothing to Disclosure
Quan-Yang Duh, MD, FACS, San Francisco, CA - Nothing to Disclosure
B. J. Hancock, MD, FACS, FRCSC, Winnipeg, MB - Nothing to Disclosure
Ronald V. Maier, MD, FACS, FRCSEd(Hon), Seattle, WA - Nothing to Disclosure
Note: Residents will receive a Certificate of Completion.
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Certificate of Completion
- 1.50 Self Assessment Credit